Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Rapt Therapeutics Inc (NQ: RAPT ) 2.250 +0.400 (+21.62%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Rapt Therapeutics Inc < Previous 1 2 3 4 5 Next > 12 Health Care Stocks Moving In Wednesday's Intraday Session Today 12:31 EDT Via Benzinga RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024 August 08, 2024 RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace RAPT Therapeutics Reports Second Quarter 2024 Financial Results August 08, 2024 From RAPT Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session June 03, 2024 Via Benzinga RAPT Therapeutics: Q4 Earnings Insights March 07, 2024 Via Benzinga Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month May 21, 2024 Via Benzinga INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm May 09, 2024 From Schall Law Via GlobeNewswire What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday? May 09, 2024 RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure. Via Benzinga Exposures Product Safety RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024 May 09, 2024 RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session May 09, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session May 09, 2024 Via Benzinga RAPT Therapeutics Reports First Quarter 2024 Financial Results May 09, 2024 Company maintains solid cash position of $141.6 million From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients April 09, 2024 From RAPT Therapeutics, Inc. Via GlobeNewswire 3 Biotech Stocks to Dump Before They Go to Zero April 09, 2024 These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling. Via InvestorPlace RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm March 11, 2024 From Bragar Eagel & Squire Via GlobeNewswire RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023 March 07, 2024 RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 07, 2024 Company maintains solid cash position of $158.9 million From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting March 05, 2024 Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings February 26, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Rivian Automotive Reports Q4 Loss, Joins Etsy, Lucid Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session February 22, 2024 U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday. Via Benzinga What's Going On With RAPT Therapeutics Stock On Wednesday? February 21, 2024 Latest developments in RAPT Therapeutics as FDA places clinical hold on Phase 2b trial for zelnecirnon in dermatitis and asthma. Stock rebounds and analyst downgrades. Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Wednesday's Intraday Session February 21, 2024 Via Benzinga Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session February 21, 2024 Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... Via Benzinga Stocks Slip Ahead Of Fed Minutes, Nvidia Earnings February 21, 2024 Stocks are lower today, with the Nasdaq Composite Index (IXIC) leading the losses as investors reassess a potentially overvalued tech sector. Via Talk Markets Topics Economy Stocks Exposures Interest Rates US Equities Crude Oil Moves Lower; Summit Therapeutics Shares Plummet February 20, 2024 U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 200 points on Tuesday. The Dow traded down 0.18% to 38,557.86 while the NASDAQ fell 1.30% to 15,570.84. The... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session February 20, 2024 Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session February 20, 2024 Via Benzinga Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today? February 20, 2024 FDA places clinical hold on RAPT Therapeutics' Phase 2 trials for zelnecirnon in atopic dermatitis and asthma. Via Benzinga Exposures Product Safety Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests February 20, 2024 The FDA put studies in eczema and asthma treatment on clinical hold. Via Investor's Business Daily Exposures Product Safety Dow Dips Over 100 Points; US Leading Economic Index Falls In January February 20, 2024 U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.35% to 38,494.51 while the NASDAQ fell 1.51% to 15,537.95. The S&P 500... Via Benzinga Topics Stocks Exposures US Equities < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.